Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Trial of ePGT121v1-LS, PGDM1400LS, and VRC07-523LS in Healthy Adults
NCT07390955Phase 1Recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Mar 2026
- Primary completion
- Aug 2027
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, open-label trial of ePGT121v1-LS in human immunodeficiency virus infection (HIV) (8 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Number and Percentage of Participants with Solicited Local Adverse Events at Week 48, Number and Percentage of Participants with Solicited Systemic Adverse Events at Week 48 and 10 more. Started Mar 2026; status: recruiting.
02
Drugs
ePGT121v1-LS
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT07390955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07390955.